
News|Videos|June 17, 2025
RX Review: RSV prevention and pediatric hospitalization
Fact checked by: Morgan Ebert, Executive Editor, Victoria Johnson
In this video, the first in a 3-part series, panelists discuss recent advancements in RSV management.
Advertisement
Advertisement
Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants and young children, placing a significant burden on families, hospitals, and the healthcare system. Recent advancements in RSV prevention, including maternal vaccination and long-acting monoclonal antibodies, are beginning to shift the clinical conversation from reactive management to proactive protection. In this HCP Live Network RX Review roundtable, moderator Albert Rizzo, MD, chief medical officer of the American Lung Association, leads a discussion on the evolving RSV landscape, with a focus on what these advances mean for pediatric care.
Related to this article

A Contemporary Pediatrics Peer Exchange panel reviews RSV risk, testing, maternal vaccination, and long-acting monoclonal antibodies, and where infants still slip through the cracks.

Completing the DTaP primary series was 96.2% effective against pertussis in Alaska children aged 6 months to 6 years during a record 2024 outbreak.

CDC confirmed the first pediatric flu death of 2026-27, linked to H1N1, as early flu activity rises in 2026.

With California WNV activity at a 5-year high, CHLA outlines age-based repellent and bite-prevention guidance for children.

Missed the AAP's new congenital measles guidance? This easy-to-read FAQ covers what pediatric clinicians need to know.

Johanna Chang, MD, offers guidance on vaccination, infection prophylaxis, and clinical warning signs in children receiving biologic therapies.

A GBD analysis of 204 countries estimated measles cases in children under 5 rose from 11.1 million in 2019 to 15.6 million in 2023.
Advertisement
Advertisement

